Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
21.90
-0.22 (-0.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
January 12, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified
Via
Benzinga
NASDAQ:EXEL is showing good growth, while it is not too expensive.
December 21, 2023
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
6 Analysts Have This to Say About Exelixis
December 13, 2023
Via
Benzinga
NASDAQ:EXEL, a growth stock which is not overvalued.
November 29, 2023
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Via
Chartmill
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
January 11, 2024
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.
Via
Chartmill
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Biotech Stocks With the Strongest Clinical Pipelines
November 08, 2023
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Via
InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
November 06, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Where Exelixis Stands With Analysts
November 02, 2023
Via
Benzinga
Earnings Outlook For Exelixis
October 31, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
October 18, 2023
There is one key reason to consider the stock.
Via
The Motley Fool
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
November 02, 2023
EXEL earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
October 28, 2023
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Exelixis Stock Is Trading Lower Today
October 23, 2023
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
October 19, 2023
These three lesser-known biotech companies are profitable and growing revenue.
Via
The Motley Fool
14 Analysts Have This to Say About Exelixis
October 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
September 15, 2023
The best may be yet to come for these companies.
Via
The Motley Fool
The Latest Analyst Ratings for Exelixis
September 13, 2023
Via
Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
October 13, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
October 02, 2023
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023
September 26, 2023
Via
Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
September 20, 2023
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
Via
InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
September 16, 2023
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...
Via
Talk Markets
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 16, 2023
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.